TLX2

Across TCGA pan-cancer cohorts, TLX2 Mutation is linked to patient survival in 7 of 34 cancer types, making it a survival-associated TLX2 data layer compared with 22 for mass-spec protein and 1 for mass-spec protein.

The strongest signal is observed in liver hepatocellular carcinoma (LIHC), where higher TLX2 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated TLX2 expression acts as an unfavorable survival marker.

LIHC, READ, and COAD are the cancer types where TLX2 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LIHC	OS	Median	All	0.195	0.777	.005	18	view →
READ	OS	Median	II,III,IV	0.187	0.644	.023	12	view →
COAD	OS	Median	III,IV	0.208	0.791	.008	9	view →
BRCA	DFS	Median	All	0.152	0.526	.034	8	view →
LGG	DFS	Median	All	0.110	0.833	<.001	6	view →
PRAD	DFS	Median	All	0.085	0.774	<.001	6	view →
UCEC	OS	Median	IV	0.231	0.592	.036	6	view →

Pink = unfavorable, green = favorable. Showing the 7 strongest of 7 lineages.

TLX2–LIHC (OS)

Open the LIHC breakdown →